Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BLP25 vaccine: Phase I data; Phase II

BRA reported data from a 17-patient Phase I trial showing that BLP25 was well tolerated

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE